Business
Geron Announces Four Imetelstat Presentations at the Virtual Edition of the European Hematology Association Annual Congress
MENLO PARK, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts
About this update from Geron Corporation
[{"type":"text","content":" MENLO PARK, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the Virtual Edition of the European Hematology Association (EHA) Annual Congress to be held online from June 11-14, 2020. The abstracts are available on the EHA website at www.ehaweb.org/congress.\n\n\n“We are pleased to report very encouraging durability data from the IMerge Phase 2 clinical trial to be presented at the upcoming EHA Annual Congress, including a median duration of 8-week transfusion independence of 88 weeks, which is the longest duration we have reported to date in this trial, and that 29% of patients were transfusion free for more than one year,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer. “We are also pleased that the potential survival benefit associated with imetelstat treatment in the IMbark Phase 2 clinical trial for patients relapsed or refractory to JAK inhibitors was correlated with other clinical benefits observed in the trial, such as symptom response, spleen volume reduction and improvement in fibrosis.”\n\n\nUpdated Efficacy and Safety Data from the IMerge Phase 2 Clinical Trial\n\n\nIMerge is a two-part Phase 2/3 clinical trial evaluating imetelstat in transfusion dependent patients with Low or Intermediate-1 risk myelodysplastic syndromes (lower risk MDS), who are relapsed after or refractory to prior treatment with erythropoiesis stimulating agents (ESAs). The primary efficacy endpoint of IMerge is 8-week red blood cell transfusion independence (RBC-TI) rate, defined as the proportion of patients not receiving any RBC transfusion during any consecutive eight weeks since entry into the trial. Key secondary endpoints include 24-week RBC-TI rate and the rate of hematologic improvement-erythroid (HI-E), defined as a rise in hemoglobin of at least 1.5 g/dL above the pretreatment level for at least eight weeks or a reduction of at least four units of RBC transfusions over eight weeks compared with the prior RBC transfusion burden.\n\n\nAbstract Title: Treatment with Imetelstat Provides Durable Transfusion Independence (TI) in Heavily Transfused Non-del(5q) Lower R...